{
    "eid": "2-s2.0-85092104472",
    "title": "Antiretroviral therapy-associated metabolic complications: Review of the recent studies",
    "cover-date": "2020-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Epidemiology",
            "@code": "2713",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Health Policy",
            "@code": "2719",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Dermatology",
            "@code": "2708",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [
        "Antiretroviral therapy",
        "HIV",
        "Lipid profile",
        "Lipodystrophy",
        "Metabolic"
    ],
    "authors": [
        "Daylia Thet",
        "Tippawan Siritientong"
    ],
    "citedby-count": 8,
    "ref-count": 57,
    "ref-list": [
        "Future challenges for clinical care of an ageing population infected with HIV: a modelling study",
        "Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis",
        "Metabolic complications associated with antiretroviral therapy",
        "Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review",
        "Lopinavir\u2013ritonavir versus nelfinavir for the initial treatment of HIV infection",
        "Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group",
        "HIV-Associated Lipodystrophy",
        "Lipodystrophy: pathophysiology and advances in treatment",
        "A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects",
        "Association between serum liver enzymes and metabolic syndrome in Korean adults",
        "A direct comparison of the effects of the antiretroviral drugs stavu-dine, tenofovir and the combination lopinavir/ritonavir on bone metabolism in a rat model",
        "AZT enhances osteoclastogenesis and bone loss",
        "Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice",
        "Evaluation of oral antiretroviral drugs in mice with metabolic and neurologic complications",
        "Distinct roles of the phosphatidate phosphatases lipin 1 and 2 during adipogenesis and lipid droplet biogenesis in 3T3-L1 cells",
        "miRNA-218 targets Lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/itonavir",
        "The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro",
        "Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy",
        "Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy\u2013 associated lipid disorders",
        "An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/ low HDL levels in treated HIV patients",
        "Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy",
        "Relationship of ethnicity and CD4 count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART)",
        "Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection",
        "Associations among race/ ethnicity, apoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy",
        "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretro-viral regimens for virologically suppressed adults with HIV-1 infec-tion: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study",
        "Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial",
        "Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal",
        "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial",
        "Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment",
        "Tenofovir DF, emtricita-bine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV",
        "Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfi-navir or efavirenz plus dual nucleosides",
        "Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobi-cistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials",
        "Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial",
        "Substitution of nevir-apine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection",
        "Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials",
        "Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial",
        "Lipid profiles for etra-virine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial",
        "Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy",
        "Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-na\u00efve HIV-1-infected patients at week 96: ARTEMIS",
        "Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA",
        "Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48",
        "Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial",
        "Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study",
        "Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS Clinical Trials Group A5260s",
        "Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients",
        "Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial",
        "Adverse events of raltegravir and dolutegravir",
        "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)",
        "Simplification to dual therapy (atazanavir/ritonavir+ lamivudine) versus standard triple therapy [atazanavir/ritonavir+ two nucleos (t) ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)",
        "Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial",
        "Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir",
        "Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, rando-mised trial",
        "Association between the occurrence of adverse drug events and modification of first-line highly active antiretroviral therapy in Ghanaian HIV patients",
        "Nutritional issues and positive living in human immunodeficiency virus/AIDS"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Thailand International Cooperation Agency"
    ]
}